<DOC>
	<DOCNO>NCT00979667</DOCNO>
	<brief_summary>To evaluate efficacy oseltamivir , compare placebo arm zanamivir control arm respect symptom duration among patient infect influenza A ( H1N1 ) virus .</brief_summary>
	<brief_title>A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection</brief_title>
	<detailed_description>The outbreak respiratory illness Mexico begin March 2009 cause swine origin influenza A ( H1N1 ) virus ( S-OIV ) recognize previously pig human . As 17 May 2009 , 39 country officially report 8480 case influenza A ( H1N1 ) infection . The H1N1 influenza A virus appear sensitive oseltamivir zanamivir vitro , resistant amantadine rimantadine . This study test oseltamivir , zanamivir placebo arm first line treatment human swine influenza infection . Through study , investigator may better understand clinical , biochemical , virological profile oseltamivir/zanamivir H1N1 virus , optimize treatment strategy among Chinese population .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>Male female patient 18 year old body weight &gt; 40kg Written inform consent Presented within 48 hour onset influenzalike illness Presumptive diagnosis H1N1 satisfy follow clinical laboratory criterion : Clinical criterion Fever &gt; 38 oC ( Infrared Forehead Thermometer use measure Temporal Artery Temperature skin ) AND At least one upper respiratory tract infection ( cough , run nose , sore throat ) Laboratory criterion Positive rapid test result influenza A ( Influenza Rapid Diagnostic test ) within 48 hour onset flulike symptom Age 18 year Persons lack ability care Patient critical condition already develop severe respiratory distress hypoxaemia presentation Pregnancy lactation Coexisting liver disease Coexisting cardiovascular disease except stable hypertension without complication Coexisting chronic pulmonary disease Coexisting immunocompromised medical condition concurrent immunosuppressive therapy Renal failure Terminal malignancy terminal endorgan failure estimate lifeexpectancy le 3 month Known intolerance oseltamivir zanamivir Known history significant neurological disorder compromise respiratory function handle respiratory secretion increase risk aspiration Subjects receive oseltamivir prophylaxis H1N1 infection Subjects receive investigational drug within 1 month prior study entry Subjects mental condition render subject unable understand nature , scope , possible consequence study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Upper respiratory tract infection</keyword>
	<keyword>Influenza A</keyword>
	<keyword>Human Swine Influenza</keyword>
</DOC>